New data will be presented for Roche’s Esbriet in idiopathic pulmonary fibrosis at European Respiratory Society Congress 2015
Posted: 21 September 2015 |
Roche announced that new Esbriet® (pirfenidone) data analyses in idiopathic pulmonary fibrosis (IPF) will be presented at the European Respiratory Society (ERS) congress in Amsterdam, 26-30 September 2015…
- Nine abstracts and two symposia demonstrate advances in the Roche respiratory portfolio
- Presentation of pooled data analysis on the effect of Esbriet on mortality after initiating treatment in patients with idiopathic pulmonary fibrosis (IPF)1,2
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that new Esbriet® (pirfenidone) data analyses in idiopathic pulmonary fibrosis (IPF) will be presented at the European Respiratory Society (ERS) congress in Amsterdam, 26-30 September 2015. Roche is supporting nine different abstracts on IPF data. In addition, Roche is sponsoring two medical symposia to explore treatment strategies in IPF and to highlight the importance of personalised medicines for people with severe asthma.
“Roche is committed to bringing transformative medicines to people with severe respiratory diseases,” said Sandra Horning, M.D., Roche’s Chief Medical Officer and Head of Global Product Development. “Our focus at this meeting will be on new data with Esbriet in idiopathic pulmonary fibrosis and the emerging science on the importance of personalised medicines for severe asthma.” Roche research being presented as part of the ERS 2015 scientific programme and ongoing respiratory research will be showcased during the Roche media event from 13:15–14:30 CEST on Tuesday, 29 September, 2015, at the Amsterdam RAI Exhibition and Convention Centre ERS Press Conference Room. Leading experts will speak about new IPF management guidelines and Esbriet clinical data and the need for personalised medicines for severe uncontrolled asthma patients. This event, independently organised by Roche, is open to European journalists who have registered as media with the ERS congress 2015.
Overview of oral and poster presentations for Roche at ERS
Presentation title | Abstract number / presentation timings (all times listed are Central European Time) |
Effect of Pirfenidone on Treatment-emergent (TE) All-cause Mortality (ACM) in Patients with Idiopathic Pulmonary Fibrosis (IPF): Pooled Data Analysis from ASCEND and CAPACITY | ORAL (OA4490) Tuesday, 29 September 14:45–16:45 |
Benefit of continued pirfenidone treatment following hospitalisation within the first six months of therapy—ad hoc analysis from three Phase III trials in patients with idiopathic pulmonary fibrosis (IPF) | ORAL (OA4491) Tuesday, 29 September 14:45–16:45 |
IPF Care, a support program for patients with idiopathic pulmonary fibrosis in the UK | POSTER (PA3695) Tuesday, 29 September 12:50–14:40 |
Pirfenidone post-authorisation safety registry (PASSPORT) update | ORAL (OA4500) Tuesday, 29 September 16:00 |
Differences in FVC decline by extent of emphysema in patients with combined pulmonary fibrosis and emphysema (CPFE) syndrome | ORAL (OA4488) Tuesday, 29 September 14:45 |
Safety and Tolerability of Pirfenidone (PFD) in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)–The LOTUSS Study | ORAL (OA4489) Tuesday, 29 September 15:00 |
PANORAMA – A Phase II, double-blind, placebo-controlled study of N–acetylcysteine in combination with pirfenidone in patients with idiopathic pulmonary fibrosis | ORAL (OA3477) Tuesday, 29 September 11:30 |
Antiacid therapy and progression free survival in idiopathic pulmonary fibrosis (IPF) | ORAL (OA3478) Tuesday, 29 September 11:45 |
Detrimental effects of medically indicated oral anticoagulation on survival in idiopathic pulmonary fibrosis (IPF) | ORAL (OA3479) Tuesday, 29 September 12:00 |
Roche will also hold two educational symposia on IPF and Type 2 asthma. The first, entitled “Strategies to improve treatment outcomes in IPF,” will be held on Sunday, 27 September, from 17:15-19:15 CEST in Room 5.2 at the congress centre. The second, entitled “Putting the spotlight on Type 2 biomarkers in severe asthma,” will take place on Monday, 28 September, from 17:15-19:15 CEST in Room 2.1.
Follow Roche on Twitter via @Roche and keep up to date with ERS 2015 news and updates using the hashtag #ERS2015.
